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Abstract
N-linked glycans covering the surface of the HIV-1 glycoprotein gp120 are of major importance for the correct folding of this
glycoprotein. Of the, on average, 24 N-linked glycans present on gp120, the glycan at Asn260 was reported to be essential
for the correct expression of gp120 and gp41 in the virus particle and deletion of the N260 glycan in gp120 heavily
compromised virus infectivity. We show here that gp160 containing the N260Q mutation reaches the Golgi apparatus
during biosynthesis. Using pulse-chase experiments with [35S] methionine/cysteine, we show that oxidative folding was
slightly delayed in case of mutant N260Q gp160 and that CD4 binding was markedly compromised compared to wild-type
gp160. In the search of compensatory mutations, we found a mutation in the V1/V2 loop of gp120 (S128N) that could
partially restore the infectivity of mutant N260Q gp120 virus. However, the mutation S128N did not enhance any of the
above-mentioned processes so its underlying compensatory mechanism must be a conformational effect that does not
affect CD4 binding per se. Finally, we show that mutant N260Q gp160 was cleaved to gp120 and gp41 to a much lower
extent than wild-type gp160, and that it was subject of lysosomal degradation to a higher extent than wild-type gp160
showing a prominent role of this process in the breakdown of N260-glycan-deleted gp160, which could not be
counteracted by the S128N mutation. Moreover, at least part of the wild-type or mutant gp160 that is normally targeted for
lysosomal degradation reached a conformation that enabled CD4 binding.
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Introduction
The envelope glycoprotein of the human immunodeficiency
virus (HIV), gp160, consists of surface subunit gp120 and
transmembrane subunit gp41. Gp120 is densely covered by N-
linked glycans. This glycan shield protects the virus by hiding
immunogenic epitopes, thus preventing efficient neutralization by
the immune system. Several studies have indicated that the
creation of ‘‘holes’’ in the glycan shield by removal of as few as two
glycans, can lead to the production of new neutralizing antibodies
against the previously hidden epitopes [1–3]. Therefore, the
maintenance of an intact glycan shield is of utmost importance for
the survival of HIV in the host.
In eukaryotes, protein N-glycosylation takes place in the
endoplasmic reticulum (ER), resulting in high-mannose-type N-
linked glycans covalently coupled to the nascent protein. In the
Golgi apparatus, which contains a variety of glycosidases and
glycosyltransferases, O-linked glycans are added and the high-
mannose type N-glycans are processed. It is currently believed that
high-mannose-type N-glycans promote protein folding in the ER
and that the extensive processing of these glycans into complex-
type glycans in the Golgi apparatus allows the further stabilization
of functional protein conformations [4]. However, not all high-
mannose-type N-glycans on the HIV envelope gp120 are
processed to complex-type glycans. In particular, in many viral
envelope glycoproteins, a significant percentage of N-glycans
remains high-mannose-type.
The nature of the N-glycans on HIV gp120 is still a matter of
debate. Several studies, performed on both recombinant gp120 or
gp120 derived from persistently-infected human CD4+ T cells,
suggested that at least half of the N-glycans present on the surface
of the HIV envelope are complex-type oligosaccharides [5,6].
However, other studies have indicated that the glycans on HIV
gp120 are predominantly high-mannose-type [7,8], but that the
glycan distribution changes in favour of complex-type glycans
when gp120 is recombinantly produced. In addition, when
studying gp120 derived from pseudoviral production systems or
infectious molecular clones, such as pLAI-JRCSF, the expression
level of gp120 seems to influence the glycosylation profile: the
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more envelope is expressed, the higher the high-mannose-type N-
glycan abundance [7].
Several glycans are very important for viral infectivity. It has
been reported that the glycan at amino acid position N260 is
indispensable for efficient HIV infection of its target cells. This
finding is valid for multiple HIV-1 strains including clade B [9–12]
and clade BC [12]. This N-glycan has earlier been determined to
be high-mannose-type when gp120 is expressed in Chinese
hamster ovary cells [6]. We have recently shown that mutations
in the N-glycosylation motif 260NGS262 result in an almost
complete annihilation of gp120/gp41 incorporation in the virus
particle envelope [13]. Mutations destroying this particular
glycosylation motif in gp120 impede proper trafficking and
subsequent incorporation of the envelope glycoprotein to the
plasma membrane. In this study, we further investigated the
molecular mechanisms behind this improper incorporation of the
mutant gp120 in the viral envelope.
Materials and Methods
Cells
Human T lymphocytic C8166 cells were obtained from the
American Type Culture Collection (Manassas, VA) and were
cultivated in RPMI-1640 medium (Invitrogen, Merelbeke, Bel-
gium) supplemented with 10% fetal calf serum (FCS) (Sigma,
Bornem, Belgium), 1% streptomycin, 2 mM L-glutamine and
75 mM NaHCO3. HEK293T cells were purchased from the
American Type Culture Collection and cultivated in Dulbecco’s
Modified Eagle Medium (Invitrogen) supplemented with 10%
FCS, 1% streptomycin and 75 mM NaHCO3. HeLa cells were
grown in MEM (Invitrogen) containing 10% FCS, 1% glutamax,
1% Pen/Strep and 1% non-essential amino acids.
Plasmids
The pNL4.3-Denv-EGFP construct was used for production of
wild-type (WT) NL4.3 virus after recombination with env. For this
molecular clone, the expression of enhanced green fluorescent
protein (EGFP) in infected cells is a measurement of virus
production as described previously [14]. The construct pNL4.3-
DEnv-EGFP was a kind gift from Dr. M.E. Quin˜ones-Mateu
(Lerner Research Institute).
The construct pNL4.3DGagDPol_EGFP was derived from the
vector pNL4.3DGagPr_EGFP, which was described previously
[15]. The pol gene was removed by inverse PCR using the
Herculase II DNA polymerase (Agilent Technologies, Diegem,
Belgium). The primers 59-CGACGCTCTCGCACC-
CATCTCTG-39 (position 785–807 in HIV-1 NL4.3 [Genbank
accession number M19921]) and 59-CACARGGAAAAGAT-
TAGTAAAACACCATATGTATATTTC-39 (position 5106–
5135) were used to delete the entire pol gene and were a kind
gift from Prof. K. Van Laethem. The parental DNA was digested
with DpnI (Fermentas, Leuven, Belgium) and the vector was self-
ligated using the Quick Ligation kit (New England Biolabs,
Leiden, The Netherlands). Correct removal of the pol gene and
ligation of the vector was confirmed by restriction enzyme
digestion of the vector and vector sequencing.
For transient transfection of WT and mutant gp160 in pulse-
chase analysis we constructed a plasmid containing a CMV
promoter and IntronA [16], followed by the HIV-1 LAI gp160
sequence. The plasmid, which we called pMQ, allows high
transient expression of gp160 without codon optimization.
Site-directed mutagenesis of gp120
The plasmid pBlue-env which encodes the env gene [17,18] was
used to generate gp120 mutant virus strains with mutations at
amino acid positions 260 (N to Q), 120 (V to A), 128 (S to N) and
302 (R to I). These mutations were introduced into pBlue-env
using the Quikchange Site-Directed Mutagenesis Kit (Agilent
Technologies). Plasmid DNA was purified by the PureLink Quick
Plasmid Miniprep Kit (Invitrogen). The presence of the mutations
was confirmed by sequencing the gp120 gene as described
previously [19].
Mutation N260Q, alone or in combination with mutation
S128N in gp120 were also introduced in vectors pNL4.3DGagD-
Pol_EGFP and pMQ, using the same strategy as described above.
Generation of mutant virus by env chimeric virus
technology
The generation of mutant virus was performed as described
previously [20]. Briefly, HEK293T cells were transfected with
10 mg of linearized pNL4.3-DEnv-EGFP and 2 mg of isolated
PCR product of the WT or mutant HIV-1 envelope glycoprotein,
using the calcium chloride method. Three days post transfection,
the recombinant virus and/or the transfected 293T cells were
harvested.
To study the effect of lysosomal inhibitors on the processing of
the viral envelope, 20 mM chloroquine was added to the 293T
cells 30 minutes before the addition of viral DNA.
Virus evolution
Evolution experiments were adapted from experiments de-
scribed before [21,22]. Briefly, 1.106 C8166 cells were transfected
using the Amaxa Nucleofector Technology (Lonza, Verviers,
Belgium) with 10 mg of the plasmid pNL4.3-DEnv-EGFP, together
with 2 mg of isolated PCR product of the envelope of HIV-1,
containing the N260Q mutation. The spread of virus was
monitored by fluorescence microscopy, based on the expression
of EGFP. Medium was harvested at regular time points and added
to uninfected cells. When infection was established, the virus was
harvested and sequenced as described before [19].
Infectivity of WT and mutant virus strains
To determine the infectivity of the virus strains with compen-
satory mutations in gp120, different amounts of virus (5,000–
2,500–1,250–625–312.5 pg p24), harvested from transfected 293T
cells, were added to 30.000 C8166 cells in a total volume of
200 ml. Three days post infection, the cells were fixed with 3%
paraformaldehyde and infection was monitored with the FACS-
CantoII flow cytometer (BD biosciences, Erembodegem, Belgium).
Expression of gp160, gp120 and gp41 in the virus
particle and in the transfected 293T cell
The expression levels of the envelope proteins gp160, gp120
and gp41 in both virus particles and transfected 293T cells were
determined by western blot (WB) analysis as described before [13].
In the case of WB on virus lysates, 50 ng of p24 was loaded onto a
4–12% Bis-Tris PAGE gel (Invitrogen), while for cell lysates 2 ng
of p24 was loaded.
Cell lysates were also subjected to endoglycosidase H (EndoH)
digestion (New England Biolabs), according to the manufacturer’s
protocol. An amount of 2 ng of p24, present in the cell lysates, was
denatured with the glycoprotein-denaturing buffer supplied by the
manufacturer. After a 10-minute incubation at 99uC, samples
were cooled down and G5 reaction buffer was added. Finally, 1 ml
of EndoH, corresponding to 500 U of the enzyme, was added, and
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samples were incubated at 37uC for at least 3 hours. Before
loading the samples onto a 4–12% Bis-Tris gel, 4x LDS sample
buffer (Invitrogen) was added.
Finally, complete deglycosylation of the cell lysates was obtained
through peptide-N-glycosidase F (PNGaseF) digestion (Roche,
Vilvoorde, Belgium). The samples (2 ng of p24) were boiled for
10 minutes in a denaturation buffer (10 mM sodium phosphate
pH 7, 1% SDS). After addition of the incubation buffer (10 mM
sodium phosphate pH 7, 1% Triton X-100, 1 mM EDTA, 0.1%
b-mercaptoethanol) and 1 ml of PNGaseF, samples were incubated
for at least 3 hours at 37uC. Before loading the samples onto the 4–
12% Bis-Tris gel, 4x LDS sample buffer was added.
Quantification of the WB data was performed using the ImageJ
software.
MagicMark XP Western Protein Standard (Novex, Merelbeke,
Belgium) was used to estimate the molecular weight of the
proteins.
Intracellular staining of the ER and Golgi in HIV-
transfected 293T cells
For intracellular staining experiments, 293T cells were seeded in
8-well chamber slides (Ibidi, Beloeil, QC) and transfected with
pNL4.3DGagDPol_EGFP WT or N260Q gp120 constructs as
described above. Two to three days after transfection, the cells
were carefully washed with PBS, and fixed in 4% paraformalde-
hyde. Permeabilisation was done with 0.1% Triton X-100, after
which 10% normal goat serum (Invitrogen) was added for
blocking. Gp120 was detected in the transfected 293T cells using
antibody 2G12 (Polynum, Vienna, Austria). For ER and Golgi
staining, antibodies against PDI and giantin were used, respec-
tively. Corresponding secondary antibodies were either labelled
with Alexa633 (for 2G12) or Alexa568 (for the organelles) (all
purchased from Invitrogen). Images were taken using a laser
scanning SP5 confocal microscope (Leica, Diegem, Belgium).
Pulse-chase experiments
Twenty-four hours in advance, HeLa cells were transfected with
a mix of polyethylenimine (pEI) and WT or mutant DNA in a
ratio of 2.5 to 1, after which the cells were subjected to pulse-chase
analysis as described before [23]. In short, cells were starved in
medium lacking cysteine and methionine for 15–30 min and pulse
labelled for 10 min with 55 mCi/35 mm dish of Express 35S
protein labelling mix (PerkinElmer, Boston, MA). The pulse was
stopped and the chase started by the first of 2 washes with chase
medium containing an excess of cold cysteine and methionine. At
the end of each chase time, cells were cooled on ice and further
disulfide bond formation and isomerization was blocked with
20 mM iodoacetamide (IAM).
Cells were lysed and detergent lysates were subjected to
immunoprecipitation with polyclonal antibody 40336 against
gp160 or with CD4-IgG2 against the CD4-binding site. Next,
samples were deglycosylated using EndoH (Roche) as described
above, and were subjected to non-reducing and reducing (25 mM
DTT) 7.5% SDS-PAGE [23,24]. Gels were dried and exposed to
Kodak MR films for autoradiography.
Flow cytometric analysis of gp120 expression on the
surface of HIV-transfected 293T cells
293T cells were transfected with linearized pNL4.3-DEnv-
EGFP and isolated WT or mutant gp160 PCR product using the
calcium chloride method, in the absence or presence of 20 mM
chloroquine. Two or three days post transfection, the cells were
stained to detect surface gp120 using the monoclonal antibody
2G12 and a secundary antibody labelled with Alexa Fluor 647
(Invitrogen). The cells were analysed using the FACSCanto II flow
cytometer (BD Biosciences).
Quantification of soluble CD4 (sCD4) binding using an
enzyme-linked immunosorbent assay (ELISA)
This experiment was performed as described previously [13],
with some adaptations. 8-well maxisorp strips (Nunc, Erembode-
gem, Belgium) were coated with 0.5 mg of sCD4 (Sino Biological
Inc, Zoersel, Belgium) in 50 mM carbonate buffer (pH 9.6) during
2 hours at room temperature. Then, the wells were blocked for 1
hour at room temperature using PBS pH 7.4 supplemented with
0.05% Tween 20 (Sigma) and 2% milk powder ( = blocking
buffer). After washing the wells with wash buffer (PBS supple-
mented with 0.05% Tween 20), 45 ng p24 of virus lysed using
10% Triton-X100 in blocking buffer was added to the wells for 1
hour at 37uC. After washing, the wells were incubated with the
primary sheep antibody directed against gp120 (D7324; Aalto Bio
Reagents, Dublin, Ireland) in blocking buffer during 1 hour at
37uC. Afterwards, the wells were washed again with wash buffer
and were incubated for 1 hour at 37uC with the secondary
antibody labelled with alkaline phosphatase in blocking buffer.
Substrate buffer (1 mg/ml p-nitrophenyl phosphate (Sigma)
dissolved in 10% diethanolamine, pH 9.8, with 0.5 MgCl2) was
added to the wells after sufficient washing. Following 30 minutes
incubation, the absorbance at 405 nm as a measurement of virus
binding to CD4 was determined using the Safire 2 microtiter plate
reader (Tecan, Mechelen, Belgium).
Results
Mutated N260Q gp160 proceeds from the endoplasmic
reticulum to the Golgi
We have previously shown that in HIV-transfected 293T cells,
gp160 containing the N260Q mutation appeared in the Golgi for
further processing [13]. To confirm the efficient transport of
gp160 to the Golgi, we performed intracellular staining of 293T
cells transfected with WT or mutant gp160. Figure 1 shows the co-
localization of gp160 with markers for the ER (PDI) and the Golgi
apparatus (giantin). A large fraction of both WT and mutant
N260Q gp160 resided in the ER, which is the organelle in which
protein biosynthesis takes place. In steady state, most of the gp160
shows ER localization due to its slow folding kinetics [23]. Co-
staining was also seen in the Golgi apparatus for both WT and
mutant N260Q gp160 (Fig. 1). These results indicated that (WT
and mutant) gp160 is continuously produced in the ER, but also
that (at least a fraction of) the mutant envelope proceeded to the
Golgi.
An important step during the processing of gp160 is the
conversion of part of the high-mannose-type N-glycans (added to
asparagines during polypeptide synthesis) into complex-type N-
glycans. This conversion takes place in the Golgi where addition of
an N-Acetylglucosamine (GlcNAc) residue to the glycan represents
the first step in the conversion to a complex-type glycan [25]. To
confirm that mutant N260Q gp160 is processed in the Golgi, we
treated cell lysates of transfected 293T cells with EndoH, which
only cleaves high-mannose-type and hybrid-type glycans, but not
complex-type glycans. As can be seen from the Western blot
analysis in Figure 2, Panel A, WT and mutant gp160 were EndoH
sensitive, indicating that the majority of WT and mutant N260Q
gp160 had high-mannose-type glycans and resided in the ER.
The same samples were also treated with PNGaseF, which
cleaves off all N-linked glycans and converts the asparagines
(lacking the glycan) into aspartic acid residues. This digestion
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resulted for both WT and mutant gp160 in a major band with a
slightly lower molecular weight than the EndoH-treated samples
because EndoH leaves 1 GlcNAc attached to the asparagine,
which is cleaved off by PNGaseF digestion. These results indicate
that both EndoH and PNGaseF digested gp160 are deglycosylated
(Fig. 2, Panel A), indicating that the vast majority of both WT and
mutant N260Q gp160 were not yet processed in the Golgi
apparatus. Whereas Fig. 2A shows a Western blot analysis of cell
lysates exposed to an anti-gp41 antibody, Fig. 2B shows an
identical Western blot analysis of cell lysates exposed to an anti-
gp120 antibody. This explains why in the non-treated lysates, a
double band was observed that corresponds to glycosylated gp160
and gp120. The lower band (approximately 90–95 kDa) seen in
both Fig. 2A and 2B represents most likely untranslocated gp160
that did not get glycosylated and still had its signal peptide. The
predominant single upper band that appeared in the mutant cell
lysates (instead of a double band in the WT cell lysates) is
suggestive for the presence of mainly uncleaved gp160. This
indicates that the mutant envelope gp160 is less efficiently cleaved
to gp120+gp41 than WT gp160.
Mutation in the V1/V2-loop of gp120 can only
moderately compensate for the loss of infectivity due to
the N260Q gp120 mutation
Previous attempts by site-directed mutagenesis to introduce new
glycosylation sites in the proximity of the 260NGS262 glycosyl-
ation motif failed to restore the infectivity of the N260Q gp120
mutant virus [13]. However, continuous passaging of seemingly
uninfectious virus in cell culture has been shown earlier to result in
the selection of compensating mutations [26,27]. We therefore
investigated whether the detrimental loss of infectivity due to the
N260Q mutation in gp160 could be compensated for by the
introduction of a second-site suppressor mutation in gp160. For
this purpose, C8166 cells were transfected with the HIV-1
construct encoding mutant N260Q gp160. After long-term
passaging of these transfected C8166 cells, two mutations occurred
in the V1/V2-loop of gp120 that allowed cell-free infection (albeit
still poor) of mutant HIV containing N260Q gp160. The mutation
at amino acid position 120, changing a valine into an alanine,
appeared first during the virus evolution assays as an addition to
the pre-existing N260Q gp120 mutation. Later on, the S128N
mutation appeared in combination with V120A and N260Q. At
the end of the selection process, solely the S128N and N260Q
gp120 mutations were retained in gp160. The N260Q mutation in
gp120 apparently did not revert to WT.
To determine to what extent infectivity was restored by the V1/
V2-mutations, we introduced the single V120A and S128N
mutations and the combined V120A/S128N mutations into the
mutant N260Q gp160 background. Figure 3 shows that the
V120A and V120A/S128N gp120 mutations were virtually
unable to restore infectivity of mutant N260Q gp160 HIV-1.
On the other hand, the single S128N mutation in the N260Q
gp160 background allowed about 7% infection at the highest dose
of virus added to the uninfected C8166 cell cultures (Fig. 3), thus
being still more than 10 times less infectious than WT virus.
Despite long-term passaging (.30 passages) of the mutant
N260Q/S128N gp120 virus, mutations that further increased viral
infectivity did not arise. It has been reported earlier that an
arginine to isoleucine mutation at amino acid position 302 in
gp160 restored infection potential of the mutant N260Q/S128N
virus [28]. Although this mutation was not selected in our
experiments, we aimed to confirm these observations by
introducing the R302I mutation in the HIV-1 gp160 that already
contained the N260Q, N260Q/V120A, N260Q/V120A/S128N
and N260Q/S128N background mutations. Different concentra-
tions of these mutant viruses were added to C8166 cell cultures,
and the degree of infection was determined based on the
appearance of EGFP by FACS analysis. The R302I mutation on
its own did not alter the infectivity of the virus. In contrast to the
report by Willey et al. [28] none of the viruses that contained the
R302I mutation in combination with the N260Q or N260Q/
S128N gp120 mutations showed any infectivity gain (data not
shown). Thus, we identified S128N in the V1/V2-loop as a
compensatory mutation to N260Q (Fig. 4), which restores mutant
virus infectivity up to ,10% of WT levels.
The S128N compensatory mutation in gp120 has no
measurable effect on the gp120/gp41 levels in mutant
virus particles
We have previously shown that the N260Q mutation in gp160
of HIV-1 is associated with dramatically lower levels of gp120 and
gp41 expression in the virus particle [13]. Since the S128N
mutation partially restored viral infectivity, we wondered whether
this was caused by increased incorporation of gp120 and gp41 in
the virus particle. To test this hypothesis, the virus in the cell
culture medium of transfected 293T cells was concentrated, lysed,
and subjected to WB analysis. Although the gp120 and gp41 levels
in mutant N260Q gp120 virus were somewhat higher in this
experiment than previously reported, its levels were still markedly
lower than WT levels (Fig. 5A, 5B, 5C: data without chloroquine).
Introduction of the S128N mutation in the mutant N260Q gp160
virus did not increase the expression and incorporation of both
gp120 and gp41 in the virus particle.
Figure 1. Intracellular staining of HIV-transfected HEK293T
cells. The ER and Golgi apparatus (green) were labelled with an anti-
PDI and an anti-giantin antibody, respectively. Gp120 (red) was
visualized with antibody 2G12. Overlay of gp120 and the ER or Golgi
is shown as orange/yellow.
doi:10.1371/journal.pone.0101181.g001
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Figure 2. Western blot analysis of glycosidase-treated cell lysates derived from wild-type (WT) and mutant N260Q gp160 HIV-
transfected HEK293T cells. Cell lysates were treated with either endoglycosidase H (EndoH) or peptide-N-glycosidase F (PNGaseF). The
glycoprotein gp160 was detected with an anti-gp41 antibody (A) or an anti-gp120 antibody (B). GAPDH was used as an equal-sample loading control.
M: MagicMark XP Western Protein Standard (Novex).
doi:10.1371/journal.pone.0101181.g002
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Maturation of mutant N260Q gp160 and mutant N260Q/
S128N gp160 is delayed versus WT gp160
We next performed pulse-chase experiments with WT, N260Q
gp160 and N260Q/S128N gp160 to study the effect of these
mutations on the kinetics and yields of oxidative folding in the ER.
During a short pulse-labelling with [35S] methionine and [35S]
cysteine, all newly synthesized proteins were radioactively labelled.
This cohort of proteins was subsequently followed over time,
allowing us to monitor gp160’s oxidative folding, signal peptide
cleavage and gp120 shedding. After immunoprecipitation of
detergent cell lysates with polyclonal anti-gp160 antibody and
deglycosylation, gp160 samples were subjected to non-reducing
and reducing SDS-PAGE.
As reported earlier, gp160’s signal peptide is cleaved post-
translationally [23,29]. On a reducing gel deglycosylated gp160
with its signal peptide still attached, had an apparent molecular
weight of,100 kDa (Fig. 6A). After,15 min, a second band with
increased mobility appeared representing signal peptide-cleaved
gp160. Over time, virtually all gp160 lost its signal peptide.
Gradually, the signal intensity decreased, which was due to a
decrease in cell-associated gp120 since cleavage of the signal
sequence results in env trimerization, transport to the Golgi and
subsequently to the plasma membrane where gp120 sheds from
gp41. This is demonstrated in Figure 6C, where gp120 in the
supernatant is shown.
On a non-reducing gel the increasing number of disulfide bonds
formed during folding increased compactness and hence mobility
of gp160 (Fig. 6B). Immediately after synthesis, gp160 ran as a
smear, representing folding intermediates with incomplete or non-
native sets of disulfide bonds. The folding intermediates moved
into a single band as disulfide bond formation and isomerization
continued. This single band represented native, completely folded
gp160.
Figure 6B, showed slightly delayed maturation of both N260Q
and N260Q/S128N gp160. While signal peptide cleavage seemed
similar to WT gp160 (Fig. 6A), fewer molecules formed native
gp160 and cell surface arrival and shedding were delayed (Fig. 6C).
The delay caused by N260Q was not diminished by the addition
of S128N. The compensatory mutation hence did not markedly
affect oxidative folding of N260Q gp160.
Only a minority of ER-lumenal mutant N260Q gp160 and
N260Q/S128N gp160 is CD4-binding competent
We demonstrated earlier that mutant N260Q gp160 was CD4-
binding compromised [13]. Since the compensatory mutation
S128N did not improve overall oxidative folding of gp160 we
wondered whether it affected CD4 binding. Hence, we performed
pulse-chase analyses as described above. The lysates were pulled-
down with CD4-IgG2 and subjected to SDS-PAGE after
deglycosylation. WT gp160 showed little recognition by CD4-
IgG2 immediately after synthesis (Fig. 7, upper panel, lane of
0 min). The amount of bound gp160 increased over time. On a
non-reducing gel mainly oxidized gp160 that ran in the position of
native protein efficiently bound to CD4 (Fig. 7, lanes of 15 min up
to 4 h). This is in agreement with the discontinuous nature of the
CD4-binding epitope of gp160. Gp160 needs to fold to some
degree to become CD4-binding competent. Mutant N260Q gp160
was recognized much less by CD4-IgG2 than WT gp160 (Fig. 7,
middle panel). The signal intensity was strongly decreased while
total quantity of gp160 was not different in the mutant (see Fig. 6).
Hence, a fraction of mutant N260Q gp160 folded properly and
became CD4-binding competent but the majority failed to do so.
The compensatory mutation S128N did not visibly improve
recognition of mutant N260Q gp160 by CD4-IgG2 (Fig. 7, lower
panel). We concluded that lack of the glycosylation site at position
260 severely compromised formation of the CD-binding site and
the compensatory mutation in the V1/V2-loop (S128N) did not
restore CD4-binding ability.
Figure 3. Infectivity of WT and mutant virus strains. Different
concentrations of (WT and mutant) virus were added to C8166 cell
cultures. Three to four days post infection, the viral infection was
quantified by FACS analysis. Data (6 SD) are the means of 2 to 3
independent experiments.
doi:10.1371/journal.pone.0101181.g003
Figure 4. Ribbon diagram representation of core gp120 with
indication of Asn260 and Ser128. In the shown orientation, the
viral envelope would be on top of the picture and the cellular target
membrane on the bottom of the picture. Asn260 is positioned in the C2
region. Ser128 can be found at the base of the V1/V2 loop region.
Amino acid numbering is based on HIV-1 strain NL4.3, and corresponds
with amino acids Asn262 and Ser128 in HIV-1 strain HXB2. Figure
adopted from Kwong et al. 1998 [36].
doi:10.1371/journal.pone.0101181.g004
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Figure 5. Western blot analysis of the incorporation levels of gp160, gp120 and gp41 in viral particles. (A) Analysis of the level of
gp160, gp120 and gp41 incorporation in virus particles, produced in the absence or presence of the lysosomal inhibitor chloroquine. P24 was
quantified as an equal loading control. (B–C) Relative protein levels as quantified based on panel A using the ImageJ software, and normalized to
equal p24 levels.
doi:10.1371/journal.pone.0101181.g005
Figure 6. Pulse-chase experiments to study signal peptide cleavage, oxidative folding and gp120 shedding. HeLa cells transfected
with WT or mutant gp160 were pulsed with Express 35S protein labelling mix during 10 min and chased with cold cysteine and methionine for the
indicated time. Films in panel A were exposed for 7 days and in panel B and C for 14 days. (A) Reducing (R) SDS-PAGE to study signal peptide
cleavage. (B) Non-reducing (NR) SDS-PAGE to study oxidative folding. (C) Detection of shed gp120 in culture medium. SP: signal peptide.
doi:10.1371/journal.pone.0101181.g006
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The N260Q mutation increases lysosomal degradation of
gp160, gp120 and gp41
Incorrectly folded proteins that do not pass the quality control
in the ER are normally degraded by the proteasome after
ubiquitination. However, certain proteins with minor conforma-
tional defects can pass the quality control of the ER and transit to
the Golgi, where they are nonetheless detected as misfolded and
diverted to lysosomes for degradation [30]. Given the fact that
eventual expression of either glycoprotein on the viral envelope
surface was low, we investigated the possibility that mutant
N260Q gp120 and gp41 are degraded in lysosomes.
For this purpose, we added chloroquine to the 293T cells at the
time of transfection, and the viruses derived from these cells,
together with the cell lysates, were subjected to Western blot
analysis. Chloroquine is known to block lysosomal activity.
Figure 5A shows that in the case of WT virus, the addition of
chloroquine to the 293T cells led to the incorporation of uncleaved
gp160 in the virus particle. As shown previously, the N260Q
mutation in gp120 is associated with a much lower incorporation
of gp120 and gp41 in the virus particle envelope [13]. However,
mutant N260Q gp120 virus derived from chloroquine-treated cells
showed an increased level of gp120, gp41, and in particular gp160,
in the virus particle (Fig. 5A, 5B, 5C). The relative increase of
incorporated gp160, gp120 and gp41 was more pronounced for
mutant N260Q gp120 HIV compared to WT HIV, suggesting
that the N260Q mutation in gp160 promoted lysosomal degra-
dation. The Western blot analysis in Fig. 5A for the mutant
envelope confirms our findings (shown in Fig. 2B) that mutant
gp160 is much less efficiently cleaved than wild-type gp160. Again,
mutation S128N did not change the findings for N260Q gp160,
whether with or without chloroquine.
WB analysis of the cell lysates of transfected 293T cells clearly
showed that chloroquine treatment was accompanied with a
massive increase in both gp160 and gp41 (Fig. 8).
To confirm the data obtained by WB analysis, HIV-transfected
cells were stained with the monoclonal antibody 2G12 to detect
gp120 on the cellular surface. Therefore, 293T cells were
transfected with WT, N260Q or N260Q/S128N gp160-encoding
HIV, in the absence or presence of chloroquine. It was shown that
inhibition of lysosomal activity had a limited negative effect on the
surface expression of WT gp120, while there was a marked
increase in the level of surface gp120 in the case of the N260Q
mutation (Fig. 9). Chloroquine also increased the level of N260Q/
S128N gp120 on the cell surface, although less pronounced
compared to the single mutant.
At least part of the gp160 that is targeted for lysosomal
degradation is CD4-binding competent
We finally investigated the sCD4-binding potential of virions
produced in the presence of chloroquine, to determine whether
the conformation of the otherwise lysosomally degraded gp120
enables CD4 binding. Using an ELISA, it was confirmed that WT
virus is able to bind CD4 substantially better than virus containing
the gp120 N260Q or N260Q/S128N mutations (Fig. 10). The
presence of chloroquine during virus production resulted for all
viruses in an increase in CD4 binding potential, which was most
pronounced for the N260Q gp120 mutant. This indicates that at
least part of the otherwise degraded gp120 reached a conforma-
tion that supports CD4 binding.
Discussion
The N-glycan at amino acid N260 in HIV-1 gp120 is of utmost
importance for proper infectivity of the virus against its target cells,
such as CD4+ T lymphocytes [13]. We have previously reported
that mutations affecting the N260 glycosylation motif – either in
the asparagine residue, or in the serine residue – severely impair
incorporation of gp120 and gp41 in the mutant virus particles
[13]. Here we show that, in steady state, gp160 is largely found in
the ER because it folds slowly and takes a long time to exit the ER.
Figure 7. Immunoprecipitation of WT and mutant gp160 with
CD4-IgG2. Aliquots of detergent lysates from Figure 6 were used for
gp160 pull-down with CD4-IgG2, deglycosylation and subjection to
SDS-PAGE. Films were exposed for 1 month.
doi:10.1371/journal.pone.0101181.g007
Figure 8. Western blot analysis of the expression levels of
gp160, gp120 and gp41 in virus transfected HEK293T cells, in
the absence or presence of the lysosomal inhibitor chloro-
quine. WT, N260Q and N260Q/S128N virus transfected HEK293T cells
were lysed and subjected to WB analysis (2 ng of p24 protein), to detect
gp160, gp120 and gp41 in the cell lysates. GAPDH was used as an equal
loading control.
doi:10.1371/journal.pone.0101181.g008
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These results correspond to what is reported in literature [23].
Additionally we show that mutant N260Q gp160 folds even slower
than WT gp160. Although the infectivity of N260Q gp160 HIV
could be somewhat increased by the introduction of the
compensatory mutation S128N in gp160, this secondary mutation
was found not to result in measurably increased expression/
incorporation of the glycoprotein in the viral envelope, faster
folding kinetics or improved CD4 binding. Hence, the underlying
compensatory mechanism of the S128N mutation is currently not
known.
Moore et al. [31] used antibodies to study the conformational
changes induced by N260Q and its compensatory mutation
S128N in gp160. In contrast to our results, they observed a
complete restoration of CD4 binding upon introduction of S128N.
The authors located mutation S128N in the C1 domain, and
hence studied mostly the interaction of this domain with the C2
domain, which contains the N260 glycan. However, amino acid
S128 is located in the V1/V2-loop, and the interaction of this loop
with the C2 domain has not been investigated yet.
Willey et al. [28] reported the beneficial effect of the additional
mutation at amino acid R302I in gp120 on mutant virus
infectivity. However, even after long-term passaging of N260Q/
S128N gp120-containing virus strains, we did not select for any
additional mutation including R302I that could restore infection of
the double mutant virus to WT levels. Also, in our hands,
introduction of R302I in the N260Q/S128N gp120 background
did not increase infectivity to WT levels. Although both our and
Willey’s studies were performed in the NL4.3 background, Willey
et al. produced the mutant viruses in SW480 cells and used A3.01
cells for infectivity testing of the SW480 cell supernatants. We
suggest that the choice of producer cells and/or target cells for
infectivity testing is at the basis of this discrepancy.
The pulse-chase data indicate that at least a fraction of mutant
N260Q gp160 is processed and that gp120 is shed from transfected
cells. But what is the fate of the fraction of mutant gp160 that is
not correctly processed in our assays? Because folding is not
completed yet after the 4-h chase it is not unlikely that the
remainder will continue to fold and leave the ER. WT gp160
already may take a full day to efficiently fold all its molecules [23],
and we have not found any evidence of proteasomal degradation.
We show here that at least some N260Q gp160 is degraded in the
lysosomes, which will result in decreased incorporation of gp120
and g41 into the viral envelope. Hence, the eventual differences of
gp120/gp41 incorporation into virions must originate from
processes beyond the ER. According to Trombetta and Parodi
[30], proteins with minor conformational defects can pass the
quality control of the ER and move to the Golgi, where the defect
is nonetheless detected. These proteins then are channelled to
lysosomes for degradation. Degradation of viral proteins through
lysosomes rather than proteasomes has already been described for
hepatitis B virus envelope proteins [32], and according to Willey et
al. at least uncleaved gp160 can be degraded in lysosomes [33].
The Western blot analysis revealed that mutant N260Q gp160 is
cleaved to a much lesser extent than wild-type gp160. This is
consistent with our findings that the effect of chloroquine on the
increased gp160/gp120 (Fig. 5B) and gp41 (Fig. 5C) expression in
the virus particles is more pronounced for mutant than wild-type
envelope.
We have verified the hypothesis that the N260Q mutation in
gp160 causes increased lysosomal degradation of gp160/gp120, by
inhibiting the lysosomal degradation pathway with chloroquine, a
known inhibitor of lysosomal activity. Thus, our data corroborate
the hypothesis of increased lysosomal degradation due to the
N260Q mutation in gp160. Virus, WT or mutant, produced in the
presence of chloroquine contained increased levels of gp160,
gp120 and gp41, which were clearly more pronounced for gp160
containing the N260Q mutation. Additionally, it was shown that
Figure 9. Flow cytometric analysis of gp120 expression on the
surface of HIV-transfected HEK293T cells, in the absence or
presence of chloroquine. Two days after transfection in the absence
or presence of chloroquine to produce WT, N260Q or N260Q/S128N
virus, HEK293T cells were stained to detect gp120 on the cell surface
with the primary antibody 2G12 and a secondary anti-human antibody
labelled with Alexa Fluor 647. Data are the means (6 SEM) of 5
independent experiments.
doi:10.1371/journal.pone.0101181.g009
Figure 10. Capacity of WT and mutant virus strains, produced
in the absence or presence of chloroquine, to bind to sCD4.
45 ng p24 of virus was lysed using Triton-X100 and was brought into
contact with ELISA strips coated with sCD4. The binding efficiency was
calculated as relative to the binding of WT virus produced in the
absence of chloroquine. Data are the means (6 SEM) of 2–3
independent experiments.
doi:10.1371/journal.pone.0101181.g010
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these virions had an increased CD4-binding potential, implying
that at least part of the otherwise lysosomally degraded WT or
mutant gp120 has a conformation that is competent to bind the
primary cellular receptor CD4.
If the inhibition of lysosomal degradation improves gp160/
gp120/gp41 incorporation in the viral envelope, we could
hypothesize that virus produced in the presence of chloroquine
could have an increased viral infectivity. In two independent
experiments, one performed in duplo, wild-type virus derived from
transfected cell cultures in the absence of chloroquine proved
about 4- to 7-fold more infectious than wild-type virus produced in
the presence of chloroquine (data not shown). The N260Q and
N260Q/S128N mutant virus strains produced under similar
experimental conditions did not show measurable infectivity in
C8166 cell cultures, regardless of the presence or absence of
chloroquine during virus production (data not shown). The
decreased infectivity of WT virus produced in the presence of
chloroquine might be due to residual chloroquine present in the
virus-containing supernatant since chloroquine has been earlier
shown to have a pronounced anti-HIV activity in cell culture at
concentrations as low as 1–2 mM (reviewed in [34]). Furthermore,
Chiang et al. [35] demonstrated that virus particles produced in the
presence of chloroquine have a reduced viral infectivity due to
interference with posttranscriptional modification of gp160 in the
Golgi apparatus, resulting in decreased gp160 cleavage and
deficient modification of high-mannose-type glycans into complex-
type glycans. Therefore, HIV-1 production in the presence of
chloroquine results in virus particles with a decreased envelope
gp120 level and an increased gp160 level, resulting in an
eventually decreased viral infectivity. These findings are in
agreement with our results, which show an increased envelope
glycoprotein (gp160+gp120) level in case of wild-type or mutant
virus produced in the presence of chloroquine, and indicate that
these increased envelope glycoprotein levels do not necessarily
result in increased levels of viral infectivity since it is mostly
uncleaved, non-functional gp160 that is incorporated, instead of
functional, cleaved gp120 and gp41.
The asparagine 260 is positioned at the junction of the inner
and outer domains of gp120 (Fig. 4) [36]. This region plays a
crucial role in conformational changes in gp120 during viral entry
into CD4+ T-lymphocytes. The loss of the N260 glycan on gp120
may affect the native conformation of uncleaved gp160, thereby
inducing misfolding sensors in the Golgi apparatus, leading to
increased lysosomal degradation of the N260Q mutant glycopro-
tein. Mutant envelope glycoproteins that escape lysosomal
degradation and are incorporated into viral particles showed a
decreased CD4 binding potential, probably due to the non-
optimal gp120 conformation by the lack of the N260 glycan at the
junction between the inner and outer domains of gp120.
In addition to the gp120 N260 glycan which has been shown to
be absolutely required for HIV infectivity in clades B and BC,
Lavine et al. [11] and Wang et al. [12] showed that there are a few
other gp120 N-glycans which are also crucial for viral infectivity.
When comparing both reports, it is remarkable that HIV-1 strains
belonging to clade CRF_07 BC seem to depend more on their N-
glycans since a markedly higher number of gp120 N-glycan
deletions has been shown to result in loss of viral infectivity of
clade BC strains. In contrast, a limited number of gp120 N-glycan
deletions was shown to be crucial for clade B infectivity. However,
the gp120 N260-glycan is the only gp120 N-glycan that was shown
to be indispensable for the infectivity of all studied HIV-1 strains,
belonging to clades B and BC.
In conclusion, we demonstrated the absolute requirement of an
intact gp120 N260 glycosylation site for the biosynthesis of HIV
env glycoproteins and the infectivity of HIV-1 NL4.3 (clade B).
Moreover, we demonstrated that an increased lysosomal degra-
dation of mutant N260Q HIV env glycoproteins is involved in this
loss of viral infectivity.
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